Elevai Labs Subsidiary, Elevai Skincare, to Present at the Beauty Through Science Conference in Stockholm
29 May 2024 - 11:00PM
Elevai Labs Inc. (NASDAQ: ELAB) (“Elevai” or the “Company”), a
pioneering force in medical aesthetics, announced that Chief
Executive Officer Jordan R. Plews, PhD has been invited back and
will be presenting at the Beauty Through Science conference in
Stockholm, Sweden on Thursday May 30, 2024.
Beauty Through Science (BTS) is an annual event that gathers the
greatest minds in aesthetic medicine to share the most up-to-date,
innovative techniques and technologies within the field – in an
immersive and intimate atmosphere. BTS was founded in 2002 and has
gradually grown to host more than 1,000 participants from close to
50 countries, establishing itself as one of the most renowned
aesthetic medical meetings in the world. Physicians, plastic
surgeons and dermatologists, among other leading experts, share
knowledge to promote a holistic approach between surgical and
non-surgical procedures, focusing on the newest and best
technologies.
Details
- What: Beauty
Through Science Conference
-
Where: Waterfront Congress Center -
Stockholm, Sweden
-
When: Thursday May 30, 2024
-
Website: www.btsstockholm.com
Dr. Plews will speak as part of the session titled “Exosomes:
Key Considerations, Regulations and Results” to discuss the exosome
landscape in aesthetics today along with the benefits of exosomes
in promoting the body’s natural repair processes.
“Elevai is proud to be an official partner of Beauty Through
Science 2024," said Jordan R. Plews, PhD Chief Executive
Officer of Elevai. "I’m looking forward to sharing the latest on
exosome technology and our science-driven, data-backed approach
with the medical aesthetics and beauty community.”
About Elevai Labs, Inc.Elevai Labs Inc.
(NASDAQ: ELAB) specializes in medical aesthetics and
biopharmaceutical drug development, focusing on innovations for
skin aesthetics and treatments tied to obesity and metabolic
health. Driven by a commitment to scientific research, we aim to
transform personal health and beauty. For more information, please
visit www.elevailabs.com.
About Elevai Skincare
Elevai Skincare Inc., an Elevai Labs company, is a medical
aesthetics company developing and commercializing cutting-edge
physician-dispensed skin and hair care applications. Elevai
develops cosmetic products for the physician-dispensed market, with
a focus on leveraging novel proprietary science-backed
technologies, including its stem cell exosome technology. For more
information, please visit www.elevaiskincare.com.
Forward-Looking Statements
Certain statements in this announcement are forward-looking
statements, including, but not limited to, the Company's proposed
Offering. These forward-looking statements involve known and
unknown risks and uncertainties and are based on the Company's
current expectations and projections about future events that the
Company believes may affect its financial condition, results of
operations, business strategy, and financial needs, including the
expectation that our shares of common stock will start trading or
that the Offering will be successfully completed. Investors can
find many (but not all) of these statements using words such as
"approximates," "believes," "hopes," "expects," "anticipates,"
"estimates," "projects," "intends," "plans," "will," "would,"
"should," "could," "may" or other similar expressions in this
prospectus. The Company undertakes no obligation to update or
revise publicly any forward-looking statements to reflect
subsequent occurring events or circumstances, or changes in its
expectations, except as may be required by law. Although the
Company believes that the expectations expressed in these
forward-looking statements are reasonable, it cannot assure you
that such expectations will turn out to be correct, and the Company
cautions investors that actual results may differ materially from
the anticipated results and encourages investors to review other
factors that may affect its future results in the Company's
registration statement and other filings with the SEC.
These and other risks are described more fully in Elevai’s
filings with the Securities and Exchange Commission (“SEC”),
including the “Risk Factors” section of the Company’s Annual Report
on Form 10-K for the year ended December 31, 2023, filed with the
SEC on March 29, 2024, and its other documents subsequently filed
with or furnished to the SEC. All forward-looking statements
contained in this press release speak only as of the date on which
they were made. Except to the extent required by law, the Company
undertakes no obligation to update such statements to reflect
events that occur or circumstances that exist after the date on
which they were made.
Investor Relations Contact:Tyler Troup,
Circadian Group IRIR@elevailabs.com
Elevai Labs (NASDAQ:ELAB)
Historical Stock Chart
From Aug 2024 to Sep 2024
Elevai Labs (NASDAQ:ELAB)
Historical Stock Chart
From Sep 2023 to Sep 2024